Ex­elix­is drug fails PhI­II lung can­cer tri­al with Cabome­tyx and Tecen­triq com­bo

Ex­elix­is’ tri­al of Cabome­tyx and Tecen­triq for pa­tients with metasta­t­ic non-small cell lung can­cer failed to meet its goal of ex­tend­ing over­all sur­vival com­pared to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER